Sugi Predict

Sugi Predict / Compounds / SCHEMBL19970123

SCHEMBL19970123

SCHEMBL19970123

Cc1ccccc1-c1nc(NS(=O)(=O)c2cccc(N3CCCC3)n2)ccc1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.39
▸ TP53 P04637 1/20 0.37
▸ KMO O15229 5/20 0.37
▸ PDE10A Q9Y233 1/20 0.35
▸ CNR2 P34972 1/20 0.34
▸ NPY5R Q15761 1/20 0.34
▸ GHSR Q92847 1/20 0.34
▸ SCN1A P35498 2/20 0.33
▸ SCN8A Q9UQD0 2/20 0.33
▸ TACR1 P25103 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19968866 0.99 SCN9A (0.39) SCN9ATP53KMOPDE10ACNR2
SCHEMBL19968842 0.93 CYP1A2 (0.42) SCN9ACNR2TACR1KDM4EALDH1A1
SCHEMBL29464370 0.93 CYP1A2 (0.42) SCN9ACNR2TACR1KDM4EALDH1A1
SCHEMBL19925041 0.92 CYP1A2 (0.42) SCN9AGHSRKDM4EALDH1A1CYP1A2
SCHEMBL29464539 0.92 CYP1A2 (0.42) SCN9AGHSRKDM4EALDH1A1CYP1A2
Hydrochloric Acid SCHEMBL29464939 0.91 CYP1A2 (0.41) SCN9AKDM4EALDH1A1CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL19951433 0.91 CYP1A2 (0.41) SCN9AKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL19970078 0.90 SCN9A (0.36) SCN9ATP53KMONPY5RGHSR
SCHEMBL29464549 0.90 PRKCA (0.37) SCN9AGHSRSCN1ASCN8ACYP1A2
SCHEMBL19951426 0.90 PRKCA (0.37) SCN9AGHSRSCN1ASCN8ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 — — EP disclosed
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2021-07-20 — — US disclosed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 — — US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 SCN9A 381/4885TP53 3115/4885KMO 1893/4885
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 SCN9A 381/4885TP53 3115/4885KMO 1893/4885
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 SCN9A 381/4885TP53 3115/4885KMO 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.